Literature DB >> 16220095

Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.

Douglas K Mitchell1, Frederick L Ruben, Stefan Gravenstein.   

Abstract

This study assessed the safety and immunogenicity of a pediatric formulation of the 2003-2004 inactivated, trivalent, split virion influenza vaccine, administered in a 2-dose schedule in healthy children ages 6-36 months, of whom 94% had protective titers (> or =1/40) to at least 1 antigen. The 2003-2004 split virion influenza vaccine was safe and immunogenic in young children.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16220095     DOI： 10.1097/01.inf.0000180978.66362.d9

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  7 in total

1.  Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants.

Authors:  Carl T D'Angio; Roy J Heyne; Shahnaz Duara; Lucy C Holmes; T Michael O'Shea; Hongyue Wang; Dongwen Wang; Pablo J Sánchez; Robert C Welliver; Rita M Ryan; Kenneth C Schnabel; Caroline B Hall
Journal:  Pediatr Infect Dis J       Date:  2011-07       Impact factor: 2.129

2.  Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.

Authors:  H Keipp Talbot; Wendy Keitel; Thomas R Cate; John Treanor; James Campbell; Rebecca C Brady; Irene Graham; Cornelia L Dekker; Dora Ho; Patricia Winokur; Emmanuel Walter; Jillian Bennet; Neil Formica; Gunter Hartel; Maryanne Skeljo; Kathryn M Edwards
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

3.  Immunogenicity of the trivalent inactivated influenza vaccine in young children less than 4 years of age, with a focus on age and baseline antibodies.

Authors:  Ayumi Mugitani; Kazuya Ito; Shin Irie; Takashi Eto; Motoki Ishibashi; Satoko Ohfuji; Wakaba Fukushima; Akiko Maeda; Yoshio Hirota
Journal:  Clin Vaccine Immunol       Date:  2014-07-02

4.  Longitudinal seroepidemiologic study of the 2009 pandemic influenza A (H1N1) infection among health care workers in a children's hospital.

Authors:  Ting-Yu Yen; Chun-Yi Lu; Luan-Yin Chang; Yi-Ting Tsai; Li-Min Huang
Journal:  BMC Infect Dis       Date:  2012-04-13       Impact factor: 3.090

Review 5.  Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines.

Authors:  Shibo Jiang; Runming Li; Lanying Du; Shuwen Liu
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

Review 6.  Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety.

Authors:  Giuseppe La Torre; Alice Mannocci; Vittoria Colamesta; Valeria D'Egidio; Cristina Sestili; Antonietta Spadea
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-09-01       Impact factor: 2.576

7.  Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children.

Authors:  Terry Nolan; Peter C Richmond; Jodie McVernon; Maryanne V Skeljo; Gunter F Hartel; Jillian Bennet; Russell L Basser
Journal:  Influenza Other Respir Viruses       Date:  2009-11       Impact factor: 4.380
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.